Indian boxer Sumit Sangwan, who was to serve a one-year ban for consuming a prohibited substance, has been cleared by National Anti-Doping Agency (NADA) after the athlete proved he took the medicine unintentionally.
The former Asian Games silver medallist's doping test showed the presence of Acetazolamide and was banned for one year on December 26 last year.
The boxer is now also eligible to take part in the upcoming 2020 Tokyo Olympics. After the ban was lifted, Sangwan admitted that he faced hard times during that period but his family support helped him to tackle the situation.
"I have faced many things in these circumstances but I am taking this in a positive way because these things happened and I tackled them. I witnessed some hard times but family supported me and with the help of that I managed to face all those things," Sangwan told ANI.
"Even during this time, I used to travel to different places to practice because I knew I have not done anything wrong and will get through this thing," he added.
Earlier on December 26, NADA had taken to Twitter to announce its decision.
"Indian Boxer Sumit Sangwan had tested positive for the presence of Acetazolamide substance which comes under the category of 'Diuretics and Masking' agents. His sample was collected on 10th October 2019 while he was participating in the Elite Men Boxing Championship, 2019. (Contd.)," NADA India had tweeted.
"Today the Anti-Doping Disciplinary Panel has rendered him ineligible for a period of one year under Article 10.5.1. In the absence of any provisional suspension, his suspension ordered by the Panel shall commence from today, i.e. 26th December 2019. (Contd.)," it had said in another tweet.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
